PHK
PTGX icon

Point72 Hong Kong’s Protagonist Therapeutics PTGX Stock Holding History

Point72 Hong Kong’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,704
Closed -$135K – 2315
2022
Q1 		$135K Buy
+5,704
New +$161K ﹤0.01% 1079
2021
Q1 		– Sell
-1,945
Closed -$39K – 2131
2020
Q4 		$39K Buy
+1,945
New +$41.9K ﹤0.01% 1297
2019
Q4 		– Sell
-37
Closed – – 1401
2019
Q3 		$0 Buy
+37
New +$466 ﹤0.01% 1278
2018
Q2 		– Sell
-239
Closed -$2K – 1130
2018
Q1 		$2K Buy
239
+184
+335% +$3.46K ﹤0.01% 800
2017
Q4 		$1K Buy
+55
New +$976 ﹤0.01% 776

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Hong Kong's PTGX Position: Q2 2022 in Review

Point72 Hong Kong sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 5,704 shares — an estimated $135K sold.

Point72 Hong Kong first reported a position in PTGX in Q4 2017 and held it in 5 quarters. The position peaked at $135K in Q1 2022. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

  • Point72 Hong Kong reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 5,704 Protagonist Therapeutics shares in Q2 2022, an estimated $135K.
  • Point72 Hong Kong first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 5 quarters.
  • Point72 Hong Kong's Protagonist Therapeutics position peaked at $135K in Q1 2022.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.